ArticleOPEN ACCESS

Pirtobrutinib, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results From the Phase 1/2 BRUIN Study

Clinical Advances in Hematology and Oncology
DOI: 10.1182/blood-2021-149138
0Citations
Citations of this article
40Readers
Mendeley users who have this article in their library.

This article is free to access.

Cite

CITATION STYLE

APA

Pirtobrutinib, A Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results From the Phase 1/2 BRUIN Study. (2022, January 1). Clinical Advances in Hematology and Oncology. Millennium Medical Publishing, Inc. https://doi.org/10.1182/blood-2021-149138

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free